Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15426481 | 0.79 | L3MBTL1 (0.44) | L3MBTL1CETPADORA1TP53MAPT | |
| SCHEMBL31146057 | 0.79 | L3MBTL1 (0.44) | L3MBTL1CETPPOLBCYP1A2CYP2C9 | |
| SCHEMBL23628497 | 0.79 | L3MBTL1 (0.44) | L3MBTL1CETPPOLBCYP1A2CYP2C9 | |
| SCHEMBL14191231 | 0.78 | PRKCI (0.41) | MAPTGRM5KDM4E | |
| SCHEMBL23628469 | 0.76 | KDM4E (0.46) | L3MBTL1CETPPOLBCYP1A2CYP2C9 | |
| SCHEMBL31146283 | 0.74 | L3MBTL1 (0.43) | L3MBTL1CETPPOLBCYP1A2CYP2C9 | |
| SCHEMBL17552177 | 0.72 | MAPT (0.64) | POLBTP53MAPT | |
| SCHEMBL20715308 | 0.69 | ACHE (0.43) | CETPPOLBADORA1MAPTKDM4E | |
| SCHEMBL6110055 | 0.69 | KMT2A (0.39) | CYP1A2TP53MAPTGRM5KDM4E | |
| SCHEMBL8608832 | 0.69 | L3MBTL1 (0.44) | L3MBTL1CETPPOLBCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688748-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206339-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | L3MBTL1 4118/4885CETP 2139/4885POLB 2974/4885 |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, COQ8A | L3MBTL1 4118/4885CETP 2139/4885POLB 2974/4885 |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNT2, TNNI3, TNNC1 | L3MBTL1 3604/4885CETP 1790/4885POLB 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.